William Blair Has Negative Forecast for Danaher Q1 Earnings

Danaher Co. (NYSE:DHR) – Research analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Danaher in a report issued on Monday, January 13th. William Blair analyst M. Larew now forecasts that the conglomerate will earn $2.00 per share for the quarter, down from their previous estimate of $2.11. The consensus estimate for Danaher’s current full-year earnings is $7.49 per share. William Blair also issued estimates for Danaher’s Q2 2025 earnings at $1.92 EPS, Q4 2025 earnings at $2.53 EPS and FY2025 earnings at $8.37 EPS.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business posted $2.02 earnings per share. The firm’s revenue was up 3.1% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on DHR. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada reduced their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Citigroup dropped their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, KeyCorp lifted their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Stock Performance

Shares of Danaher stock opened at $241.94 on Wednesday. The firm has a market capitalization of $174.75 billion, a P/E ratio of 46.17, a PEG ratio of 4.23 and a beta of 0.83. Danaher has a 52 week low of $222.53 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average price of $235.07 and a 200 day moving average price of $253.45.

Hedge Funds Weigh In On Danaher

A number of hedge funds have recently bought and sold shares of the business. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher during the third quarter valued at $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.